Log in to search using one of your social media accounts:


Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)

Conclusions Enrollment in clinical trial should be the strongly encouraged in HMA failure. Sequential use of HMA could be considered as an alternative approach in the treatment of MDS after first line HMA failure if clinical trials are not available. The outcome of patients with progressive disease after treatment with HMA remains poor and continues to be an unmet need.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma